Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2013-05-08

AUTHORS

Patrick A. Kenney , Christopher G. Wood

ABSTRACT

RCC remains the most lethal of genitourinary malignancies. It will be essential to rationally integrate surgery and systemic therapy to improve outcomes in RCC. Despite substantial efforts to date, there is no current role for adjuvant therapy following nephrectomy for clinically localized disease. There are several studies in progress that aim to identify effective agents in the adjuvant setting, including mTOR and tyrosine kinase inhibitors as well as a monoclonal antibody against CA IX. For locally advanced disease, it has been proposed that neoadjuvant therapy may make unresectable disease resectable, enable partial nephrectomy, or shrink venous tumor thrombus. These theoretical goals remain in need of further study. For patients with metastatic RCC, the correct paradigm remains to be elucidated for integrating cytoreductive surgery and systemic therapy. In particular, the proper criteria for selecting patients for surgery, the benefit of cytoreduction in the targeted therapy era, and the correct order of surgery and systemic therapy are all active areas of debate and research. More... »

PAGES

155-177

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4614-7236-0_10

DOI

http://dx.doi.org/10.1007/978-1-4614-7236-0_10

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1004072217


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, MD Anderson Cancer Center, 1515 Holcombe Blvd - Unit 1373, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, MD Anderson Cancer Center, 1515 Holcombe Blvd - Unit 1373, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kenney", 
        "givenName": "Patrick A.", 
        "id": "sg:person.0672435235.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672435235.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, MD Anderson Cancer Center, 1515 Holcombe Blvd - Unit 1373, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Urology, MD Anderson Cancer Center, 1515 Holcombe Blvd - Unit 1373, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wood", 
        "givenName": "Christopher G.", 
        "id": "sg:person.01040121722.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2013-05-08", 
    "datePublishedReg": "2013-05-08", 
    "description": "RCC remains the most lethal of genitourinary malignancies. It will be essential to rationally integrate surgery and systemic therapy to improve outcomes in RCC. Despite substantial efforts to date, there is no current role for adjuvant therapy following nephrectomy for clinically localized disease. There are several studies in progress that aim to identify effective agents in the adjuvant setting, including mTOR and tyrosine kinase inhibitors as well as a monoclonal antibody against CA IX. For locally advanced disease, it has been proposed that neoadjuvant therapy may make unresectable disease resectable, enable partial nephrectomy, or shrink venous tumor thrombus. These theoretical goals remain in need of further study. For patients with metastatic RCC, the correct paradigm remains to be elucidated for integrating cytoreductive surgery and systemic therapy. In particular, the proper criteria for selecting patients for surgery, the benefit of cytoreduction in the targeted therapy era, and the correct order of surgery and systemic therapy are all active areas of debate and research.", 
    "editor": [
      {
        "familyName": "Libertino", 
        "givenName": "John A", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4614-7236-0_10", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4614-7235-3", 
        "978-1-4614-7236-0"
      ], 
      "name": "Renal Cancer", 
      "type": "Book"
    }, 
    "keywords": [
      "systemic therapy", 
      "benefit of cytoreduction", 
      "targeted therapy era", 
      "venous tumor thrombus", 
      "renal cell carcinoma", 
      "tyrosine kinase inhibitors", 
      "adjuvant setting", 
      "unresectable disease", 
      "advanced disease", 
      "neoadjuvant therapy", 
      "cytoreductive surgery", 
      "therapy era", 
      "adjuvant therapy", 
      "tumor thrombus", 
      "metastatic RCC", 
      "genitourinary malignancies", 
      "cell carcinoma", 
      "partial nephrectomy", 
      "surgery", 
      "therapy", 
      "effective agent", 
      "monoclonal antibodies", 
      "kinase inhibitors", 
      "disease", 
      "current role", 
      "nephrectomy", 
      "CA IX", 
      "Further studies", 
      "patients", 
      "RCC", 
      "cytoreduction", 
      "thrombus", 
      "malignancy", 
      "carcinoma", 
      "antibodies", 
      "mTOR", 
      "outcomes", 
      "inhibitors", 
      "study", 
      "agents", 
      "setting", 
      "correct paradigm", 
      "IX", 
      "criteria", 
      "role", 
      "substantial effort", 
      "benefits", 
      "date", 
      "need", 
      "area", 
      "progress", 
      "goal", 
      "efforts", 
      "era", 
      "research", 
      "paradigm", 
      "proper criteria", 
      "debate", 
      "order", 
      "active area", 
      "correct order", 
      "theoretical goal"
    ], 
    "name": "Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma", 
    "pagination": "155-177", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1004072217"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4614-7236-0_10"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4614-7236-0_10", 
      "https://app.dimensions.ai/details/publication/pub.1004072217"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-09-02T16:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/chapter/chapter_13.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-4614-7236-0_10"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-7236-0_10'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-7236-0_10'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-7236-0_10'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4614-7236-0_10'


 

This table displays all metadata directly associated to this object as RDF triples.

128 TRIPLES      22 PREDICATES      86 URIs      79 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4614-7236-0_10 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N84788a5b89634676af2a099d0685e19a
4 schema:datePublished 2013-05-08
5 schema:datePublishedReg 2013-05-08
6 schema:description RCC remains the most lethal of genitourinary malignancies. It will be essential to rationally integrate surgery and systemic therapy to improve outcomes in RCC. Despite substantial efforts to date, there is no current role for adjuvant therapy following nephrectomy for clinically localized disease. There are several studies in progress that aim to identify effective agents in the adjuvant setting, including mTOR and tyrosine kinase inhibitors as well as a monoclonal antibody against CA IX. For locally advanced disease, it has been proposed that neoadjuvant therapy may make unresectable disease resectable, enable partial nephrectomy, or shrink venous tumor thrombus. These theoretical goals remain in need of further study. For patients with metastatic RCC, the correct paradigm remains to be elucidated for integrating cytoreductive surgery and systemic therapy. In particular, the proper criteria for selecting patients for surgery, the benefit of cytoreduction in the targeted therapy era, and the correct order of surgery and systemic therapy are all active areas of debate and research.
7 schema:editor N9b35d2025c0c49dda6b9c550ab2dd2ba
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf Nd041ed909799408c91086a0051c13e71
11 schema:keywords CA IX
12 Further studies
13 IX
14 RCC
15 active area
16 adjuvant setting
17 adjuvant therapy
18 advanced disease
19 agents
20 antibodies
21 area
22 benefit of cytoreduction
23 benefits
24 carcinoma
25 cell carcinoma
26 correct order
27 correct paradigm
28 criteria
29 current role
30 cytoreduction
31 cytoreductive surgery
32 date
33 debate
34 disease
35 effective agent
36 efforts
37 era
38 genitourinary malignancies
39 goal
40 inhibitors
41 kinase inhibitors
42 mTOR
43 malignancy
44 metastatic RCC
45 monoclonal antibodies
46 need
47 neoadjuvant therapy
48 nephrectomy
49 order
50 outcomes
51 paradigm
52 partial nephrectomy
53 patients
54 progress
55 proper criteria
56 renal cell carcinoma
57 research
58 role
59 setting
60 study
61 substantial effort
62 surgery
63 systemic therapy
64 targeted therapy era
65 theoretical goal
66 therapy
67 therapy era
68 thrombus
69 tumor thrombus
70 tyrosine kinase inhibitors
71 unresectable disease
72 venous tumor thrombus
73 schema:name Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma
74 schema:pagination 155-177
75 schema:productId Nbfe5715bd47f4cd2b8945a1a6cd6ce9b
76 Nd58852e086884c88980e222bdb9d59aa
77 schema:publisher Nb77dad21ea834b87b332f4423d054d0a
78 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004072217
79 https://doi.org/10.1007/978-1-4614-7236-0_10
80 schema:sdDatePublished 2022-09-02T16:10
81 schema:sdLicense https://scigraph.springernature.com/explorer/license/
82 schema:sdPublisher Na15e0b16605a4d98943ef2bc4569732c
83 schema:url https://doi.org/10.1007/978-1-4614-7236-0_10
84 sgo:license sg:explorer/license/
85 sgo:sdDataset chapters
86 rdf:type schema:Chapter
87 N4593880d10c8476a9ee660e6f069af88 rdf:first sg:person.01040121722.56
88 rdf:rest rdf:nil
89 N84788a5b89634676af2a099d0685e19a rdf:first sg:person.0672435235.10
90 rdf:rest N4593880d10c8476a9ee660e6f069af88
91 N9b35d2025c0c49dda6b9c550ab2dd2ba rdf:first Nf895dd211d864f8abdcc4fb53c2b9377
92 rdf:rest rdf:nil
93 Na15e0b16605a4d98943ef2bc4569732c schema:name Springer Nature - SN SciGraph project
94 rdf:type schema:Organization
95 Nb77dad21ea834b87b332f4423d054d0a schema:name Springer Nature
96 rdf:type schema:Organisation
97 Nbfe5715bd47f4cd2b8945a1a6cd6ce9b schema:name dimensions_id
98 schema:value pub.1004072217
99 rdf:type schema:PropertyValue
100 Nd041ed909799408c91086a0051c13e71 schema:isbn 978-1-4614-7235-3
101 978-1-4614-7236-0
102 schema:name Renal Cancer
103 rdf:type schema:Book
104 Nd58852e086884c88980e222bdb9d59aa schema:name doi
105 schema:value 10.1007/978-1-4614-7236-0_10
106 rdf:type schema:PropertyValue
107 Nf895dd211d864f8abdcc4fb53c2b9377 schema:familyName Libertino
108 schema:givenName John A
109 rdf:type schema:Person
110 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
111 schema:name Medical and Health Sciences
112 rdf:type schema:DefinedTerm
113 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
114 schema:name Oncology and Carcinogenesis
115 rdf:type schema:DefinedTerm
116 sg:person.01040121722.56 schema:affiliation grid-institutes:grid.240145.6
117 schema:familyName Wood
118 schema:givenName Christopher G.
119 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040121722.56
120 rdf:type schema:Person
121 sg:person.0672435235.10 schema:affiliation grid-institutes:grid.240145.6
122 schema:familyName Kenney
123 schema:givenName Patrick A.
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672435235.10
125 rdf:type schema:Person
126 grid-institutes:grid.240145.6 schema:alternateName Department of Urology, MD Anderson Cancer Center, 1515 Holcombe Blvd - Unit 1373, 77030, Houston, TX, USA
127 schema:name Department of Urology, MD Anderson Cancer Center, 1515 Holcombe Blvd - Unit 1373, 77030, Houston, TX, USA
128 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...